Tags: Study

Trial

Entasis Therapeutics Announces Positive Topline Results for Sulbactam-durlobactam (SUL-DUR) From Phase 3 ATTACK Trial

Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
person-holding-syringe-and-vaccine-bottle-3952241

Science Versus Ivermectin Anomaly: How Fraud Works in Scientific Studies

The ivermectin scandal relates to the case of Haruko Obokata's stem cell research. In 2014, Riken Center for Developmental Biology's stem cell expert and research leader Haruko Obokata published studies regarding the development of pluripotent stem cells from the regular blood cells.
1 2 3 4 5 6 7 8

Recommended Stories